Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line

R. Morandini, H. Süli-Vargha, A. Libert, B. Loir, J. Botyanszki, K. Medzihradszky, G. Ghanem

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Four α-MSH drug conjugates have been synthesized, 2 C-terminal (Pep 3 and 4) and 2 central fragments (Pep 1 and 2), the latter being the 4-10 sequence known to be the main α-MSH-receptor-recognition site. Melphalan was introduced into each sequence at different locations. Their ability to recognize α-MSH receptors as well as their cytotoxic effects were compared in 3 cell lines: melanoma, carcinoma and fibroblast cells. Pep 1 and 2 were able to specifically bind to MSH receptors on melanoma cells by displacing labelled α-MSH from its binding sites at concentrations similar to the 4-10 heptapeptide sequence known to contain the main receptor-recognition site. They subsequently penetrate the cell, most probably by a receptor internalization mechanism, since about half of their effect could be inhibited by competition at the receptor level. Significant and selective cytotoxic effects to melanoma cells could be observed after only 2 hr exposure to the drug conjugates. Interestingly, these 2 conjugates, differing only in melphalan position, showed completely different cytotoxicity in terms of IC50 values, Pep 1 being 24 times more toxic to all cells; but the 2 were equally specific to melanoma cells. However, they both were less toxic to all cells than melphalan itself. Furthermore, Pep 1 and 2 were able to block the receptor and, unlike Pep 3 and 4, their cytotoxic effect could be significantly inhibited by an α-MSH agonist. Pep 3 and 4 were 5 to 10 times less toxic than melphalan to melanoma and carcinoma cells and 50 times less to fibroblast cells, and did not show any cell-type selectivity. They were less toxic than Pep 1 to melanoma and carcinoma cells by a factor of 2, but equally toxic to fibroblasts. In contrast, they were more toxic than Pep 2 to fibroblasts, melanoma and carcinoma by a factor of 3, 10 and 24 respectively. Our data strongly suggest a receptor-mediated cytotoxicity mechanism occurring with α-MSH central fragments in human melanoma cells due to the presence of α-MSH-specific receptors. This mechanism appeared to be both peptide- and cell-type-specific.

Original languageEnglish
Pages (from-to)129-133
Number of pages5
JournalInternational Journal of Cancer
Volume56
Issue number1
Publication statusPublished - 1994

Fingerprint

Melanocyte-Stimulating Hormones
Melphalan
Melanoma
Cell Line
Poisons
Fibroblasts
Carcinoma
Pharmaceutical Preparations
Inhibitory Concentration 50

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Morandini, R., Süli-Vargha, H., Libert, A., Loir, B., Botyanszki, J., Medzihradszky, K., & Ghanem, G. (1994). Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line. International Journal of Cancer, 56(1), 129-133.

Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line. / Morandini, R.; Süli-Vargha, H.; Libert, A.; Loir, B.; Botyanszki, J.; Medzihradszky, K.; Ghanem, G.

In: International Journal of Cancer, Vol. 56, No. 1, 1994, p. 129-133.

Research output: Contribution to journalArticle

Morandini, R, Süli-Vargha, H, Libert, A, Loir, B, Botyanszki, J, Medzihradszky, K & Ghanem, G 1994, 'Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line', International Journal of Cancer, vol. 56, no. 1, pp. 129-133.
Morandini, R. ; Süli-Vargha, H. ; Libert, A. ; Loir, B. ; Botyanszki, J. ; Medzihradszky, K. ; Ghanem, G. / Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line. In: International Journal of Cancer. 1994 ; Vol. 56, No. 1. pp. 129-133.
@article{7c081a5046dc4682ad12971d3b4bc960,
title = "Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line",
abstract = "Four α-MSH drug conjugates have been synthesized, 2 C-terminal (Pep 3 and 4) and 2 central fragments (Pep 1 and 2), the latter being the 4-10 sequence known to be the main α-MSH-receptor-recognition site. Melphalan was introduced into each sequence at different locations. Their ability to recognize α-MSH receptors as well as their cytotoxic effects were compared in 3 cell lines: melanoma, carcinoma and fibroblast cells. Pep 1 and 2 were able to specifically bind to MSH receptors on melanoma cells by displacing labelled α-MSH from its binding sites at concentrations similar to the 4-10 heptapeptide sequence known to contain the main receptor-recognition site. They subsequently penetrate the cell, most probably by a receptor internalization mechanism, since about half of their effect could be inhibited by competition at the receptor level. Significant and selective cytotoxic effects to melanoma cells could be observed after only 2 hr exposure to the drug conjugates. Interestingly, these 2 conjugates, differing only in melphalan position, showed completely different cytotoxicity in terms of IC50 values, Pep 1 being 24 times more toxic to all cells; but the 2 were equally specific to melanoma cells. However, they both were less toxic to all cells than melphalan itself. Furthermore, Pep 1 and 2 were able to block the receptor and, unlike Pep 3 and 4, their cytotoxic effect could be significantly inhibited by an α-MSH agonist. Pep 3 and 4 were 5 to 10 times less toxic than melphalan to melanoma and carcinoma cells and 50 times less to fibroblast cells, and did not show any cell-type selectivity. They were less toxic than Pep 1 to melanoma and carcinoma cells by a factor of 2, but equally toxic to fibroblasts. In contrast, they were more toxic than Pep 2 to fibroblasts, melanoma and carcinoma by a factor of 3, 10 and 24 respectively. Our data strongly suggest a receptor-mediated cytotoxicity mechanism occurring with α-MSH central fragments in human melanoma cells due to the presence of α-MSH-specific receptors. This mechanism appeared to be both peptide- and cell-type-specific.",
author = "R. Morandini and H. S{\"u}li-Vargha and A. Libert and B. Loir and J. Botyanszki and K. Medzihradszky and G. Ghanem",
year = "1994",
language = "English",
volume = "56",
pages = "129--133",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Receptor-mediated cytoxicity of α-MSH fragments containing melphalan in a human melanoma cell line

AU - Morandini, R.

AU - Süli-Vargha, H.

AU - Libert, A.

AU - Loir, B.

AU - Botyanszki, J.

AU - Medzihradszky, K.

AU - Ghanem, G.

PY - 1994

Y1 - 1994

N2 - Four α-MSH drug conjugates have been synthesized, 2 C-terminal (Pep 3 and 4) and 2 central fragments (Pep 1 and 2), the latter being the 4-10 sequence known to be the main α-MSH-receptor-recognition site. Melphalan was introduced into each sequence at different locations. Their ability to recognize α-MSH receptors as well as their cytotoxic effects were compared in 3 cell lines: melanoma, carcinoma and fibroblast cells. Pep 1 and 2 were able to specifically bind to MSH receptors on melanoma cells by displacing labelled α-MSH from its binding sites at concentrations similar to the 4-10 heptapeptide sequence known to contain the main receptor-recognition site. They subsequently penetrate the cell, most probably by a receptor internalization mechanism, since about half of their effect could be inhibited by competition at the receptor level. Significant and selective cytotoxic effects to melanoma cells could be observed after only 2 hr exposure to the drug conjugates. Interestingly, these 2 conjugates, differing only in melphalan position, showed completely different cytotoxicity in terms of IC50 values, Pep 1 being 24 times more toxic to all cells; but the 2 were equally specific to melanoma cells. However, they both were less toxic to all cells than melphalan itself. Furthermore, Pep 1 and 2 were able to block the receptor and, unlike Pep 3 and 4, their cytotoxic effect could be significantly inhibited by an α-MSH agonist. Pep 3 and 4 were 5 to 10 times less toxic than melphalan to melanoma and carcinoma cells and 50 times less to fibroblast cells, and did not show any cell-type selectivity. They were less toxic than Pep 1 to melanoma and carcinoma cells by a factor of 2, but equally toxic to fibroblasts. In contrast, they were more toxic than Pep 2 to fibroblasts, melanoma and carcinoma by a factor of 3, 10 and 24 respectively. Our data strongly suggest a receptor-mediated cytotoxicity mechanism occurring with α-MSH central fragments in human melanoma cells due to the presence of α-MSH-specific receptors. This mechanism appeared to be both peptide- and cell-type-specific.

AB - Four α-MSH drug conjugates have been synthesized, 2 C-terminal (Pep 3 and 4) and 2 central fragments (Pep 1 and 2), the latter being the 4-10 sequence known to be the main α-MSH-receptor-recognition site. Melphalan was introduced into each sequence at different locations. Their ability to recognize α-MSH receptors as well as their cytotoxic effects were compared in 3 cell lines: melanoma, carcinoma and fibroblast cells. Pep 1 and 2 were able to specifically bind to MSH receptors on melanoma cells by displacing labelled α-MSH from its binding sites at concentrations similar to the 4-10 heptapeptide sequence known to contain the main receptor-recognition site. They subsequently penetrate the cell, most probably by a receptor internalization mechanism, since about half of their effect could be inhibited by competition at the receptor level. Significant and selective cytotoxic effects to melanoma cells could be observed after only 2 hr exposure to the drug conjugates. Interestingly, these 2 conjugates, differing only in melphalan position, showed completely different cytotoxicity in terms of IC50 values, Pep 1 being 24 times more toxic to all cells; but the 2 were equally specific to melanoma cells. However, they both were less toxic to all cells than melphalan itself. Furthermore, Pep 1 and 2 were able to block the receptor and, unlike Pep 3 and 4, their cytotoxic effect could be significantly inhibited by an α-MSH agonist. Pep 3 and 4 were 5 to 10 times less toxic than melphalan to melanoma and carcinoma cells and 50 times less to fibroblast cells, and did not show any cell-type selectivity. They were less toxic than Pep 1 to melanoma and carcinoma cells by a factor of 2, but equally toxic to fibroblasts. In contrast, they were more toxic than Pep 2 to fibroblasts, melanoma and carcinoma by a factor of 3, 10 and 24 respectively. Our data strongly suggest a receptor-mediated cytotoxicity mechanism occurring with α-MSH central fragments in human melanoma cells due to the presence of α-MSH-specific receptors. This mechanism appeared to be both peptide- and cell-type-specific.

UR - http://www.scopus.com/inward/record.url?scp=0028177662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028177662&partnerID=8YFLogxK

M3 - Article

C2 - 8262669

AN - SCOPUS:0028177662

VL - 56

SP - 129

EP - 133

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -